查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080404

糖尿病治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、糖尿病類型、原產國及分銷管道分類）

Diabetes Drugs Market by Drug Class, Route Of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，糖尿病治療市場將成長至 2,174.5 億美元，複合年成長率為 11.46%。

主要市場統計數據
基準年 2025 1017.2億美元
預計年份：2026年 1130.4億美元
預測年份 2032 2174.5億美元
複合年成長率 (%) 11.46%

隨著全球糖尿病負擔加重，治療目標也從單純控制血糖轉向降低更廣泛的心血管代謝風險，糖尿病藥物市場也不斷擴大。根據國際糖尿病聯盟（IDF）統計，2021年全球有5.37億成年糖尿病患者，預計到2030年這一數字將達到6.43億，促效劑、SGLT2抑制劑、DPP-4抑制劑、二甲雙胍和複方組合藥物的需求。

此外，早期診斷、高價值治療的保險覆蓋範圍擴大、肥胖相關的第2型糖尿病以及持續血糖監測的日益普及也是推動市場成長的因素。對於產業領導企業，競爭優勢越來越依賴臨床差異化、供應可靠性、價格可負擔性、真實世界數據以及在不同醫療保健系統中支援終身糖尿病管理的能力。

糖尿病藥物研發的變革性變化

糖尿病治療格局正因一系列針對血糖控制、體重管理、心血管結果和腎臟保護的療法而改變。 GLP-1受體促效劑和雙重腸促胰島素療法正在革新處​​方模式，而SGLT2抑制劑因其在心血管和腎臟方面的益處已在多項大型臨床試驗中得到證實，正日益受到重視。

人工智慧的累積影響

人工智慧（AI）正逐漸成為糖尿病藥物發現、臨床開發、商業化和患者支援等各階段的基礎性技術。 AI模型被用於識別藥物標靶、篩檢分子、最佳化試驗設計、對患者進行分層，並從真實世界資料集中檢測安全性訊號，有助於降低糖尿病藥物研發過程中的不確定性。

全球糖尿病市場的關鍵區域洞察

亞太地區在糖尿病藥物需求方面扮演核心角色。這主要是因為中國和印度擁有全球規模最大的糖尿病患者群體之一，而這又得益於診斷率的提高、都市化進程的加快以及最新療法的普及。日本、澳洲和韓國則透過先進的保險報銷體系、較高的臨床應用率以及數位化糖尿病管理，為糖尿病藥物市場增添了價值。

針對特定族群對糖尿病藥物需求的關鍵洞察

在東協市場，隨著公共醫療體系積極應對第二型糖尿病盛行率的上升，以及基層醫療篩檢的加強，對口服降血糖藥、胰島素和新型注射療法的需求日益成長。海灣合作理事會（GCC）成員國肥胖相關糖尿病發生率較高，對高品質治療的需求強勁，尤其是在那些增加對專科醫療、數位醫療基礎設施和慢性病預防計畫投入的國家。

來自糖尿病藥物市場主要國家的見解

美國擁有龐大的糖尿病確診患者群體和完善的專科醫療網路，在糖尿病治療創新、GLP-1藥物應用、臨床試驗活動以及以支付主導的療效證據方面處於主導地位。加拿大強調公共醫療保險報銷、成本效益和公平獲取，而墨西哥則面臨著沉重的糖尿病負擔，並持續擴大基本抗糖尿病藥物和慢性病管理服務的覆蓋範圍。巴西是拉丁美洲的主要藥品市場，公共採購、私人醫療保健需求以及第2型糖尿病盛行率的不斷上升，都支撐著胰島素、口服藥物和新型藥物的持續使用。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的產品系列，這些產品不僅能控制血糖，還能管理體重，並對心血管和腎臟系統產生有益影響。企業需要投資於真實世界數據、直接比較數據、支持患者依從性的促效劑以及對保險公司至關重要的結果數據，以支持GLP-1受體激動劑、SGLT2抑製劑、胰島素和聯合治療的高階市場定位。

調查方法

本執行摘要採用系統性的二手研究框架編寫，涵蓋流行病學、監管批准、治療指南、臨床試驗證據、藥物安全監測資源、報銷政策和公共衛生資料集。主要參考文獻包括國際糖尿病聯盟 (IDF)、世界衛生組織 (EMA)、經濟合作暨發展組織 (OECD)、各國衛生組織以及同行評審的臨床文獻等權威資訊來源。

結論

糖尿病治療市場已進入一個更成熟的階段，療效、安全性、可負擔性、供應可靠性和患者預後共同決定治療的成功。龐大且不斷成長的糖尿病患者群體推動了市場需求，而治療領域的創新則正將治療重點轉向保護心血管代謝和腎功能。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 糖尿病治療市場：依藥物類別分類

  • Amylin類似物
  • GLP-1受體促效劑
  • 胰島素
    • 長效型
    • 快速起效
  • 口服降血糖藥（OADs）

第8章 糖尿病治療市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服

第9章 糖尿病治療市場：依糖尿病類型分類

  • 1型糖尿病
  • 2型糖尿病

第10章 糖尿病治療市場：依藥物來源分類

  • 品牌藥品
  • 學名藥

第11章 糖尿病藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 糖尿病藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 糖尿病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 糖尿病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton SA
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries（Julphar）
  • Johnson and Johnson
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk AS
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-434CCDA051C3

The Diabetes Drugs Market is projected to grow by USD 217.45 billion at a CAGR of 11.46% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 101.72 billion
Estimated Year [2026] USD 113.04 billion
Forecast Year [2032] USD 217.45 billion
CAGR (%) 11.46%

The diabetes drugs market is expanding as the global diabetes burden rises and treatment goals shift from glycemic control alone to broader cardiometabolic risk reduction. The International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projected 643 million by 2030, creating sustained demand for insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, metformin, and fixed-dose combination therapies.

Growth is also being shaped by earlier diagnosis, broader reimbursement for high-value therapies, obesity-linked type 2 diabetes, and expanding use of continuous glucose monitoring. For industry leaders, competitive advantage increasingly depends on clinical differentiation, supply reliability, affordability, real-world evidence, and the ability to support lifelong diabetes management across diverse healthcare systems.

Transformative Shifts in Diabetes Drug Development

The diabetes treatment landscape is being transformed by therapies that address glucose control, weight management, cardiovascular outcomes, and kidney protection. GLP-1 receptor agonists and dual incretin therapies have reshaped prescribing patterns, while SGLT2 inhibitors have gained strong clinical relevance due to demonstrated cardiovascular and renal benefits in major outcomes trials.

At the same time, insulin delivery is moving toward more patient-centric formats, including connected pens, automated dosing support, and biosimilar insulin options. Market competition is shifting from single-product efficacy claims to integrated value propositions that combine clinical outcomes, adherence support, payer evidence, and scalable manufacturing capacity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming an enabling layer across diabetes drug discovery, clinical development, commercialization, and patient support. AI models are used to identify drug targets, screen molecules, optimize trial design, stratify patients, and detect safety signals from real-world datasets, helping reduce uncertainty in diabetes drug development.

AI also strengthens diabetes care delivery through predictive analytics, remote monitoring, dose optimization, and adherence interventions. When integrated with continuous glucose monitoring, electronic health records, and pharmacy data, AI can support more personalized therapy selection while improving pharmacovigilance and market access evidence generation.

Key Regional Insights Across Global Diabetes Markets

Asia-Pacific is central to diabetes drug demand because China and India account for some of the world's largest diabetes populations, supported by rising diagnosis rates, urbanization, and expanding access to modern therapies. Japan, Australia, and South Korea add value through advanced reimbursement systems, strong clinical adoption, and digital diabetes management.

North America remains a high-value region led by the United States, where CDC data show 38.4 million people had diabetes in 2021, while Canada emphasizes public reimbursement, cost-effectiveness, and equitable access. Latin America continues to face a rising type 2 diabetes burden, with Mexico and Brazil expanding access to insulin, oral antidiabetic drugs, and newer cardiometabolic therapies through public and private channels.

Europe is shaped by EMA approvals, national health technology assessment scrutiny, guideline-driven prescribing, and biosimilar adoption across insulin and injectable therapies. The Middle East, particularly high-income Gulf countries, shows strong demand linked to obesity, sedentary lifestyles, and investment in specialty diabetes care, while Africa presents substantial unmet need where affordability, diagnosis gaps, medicine availability, and cold-chain infrastructure remain decisive barriers.

Key Group Insights for Diabetes Drug Demand

ASEAN markets show rising demand for oral antidiabetic drugs, insulin, and newer injectable therapies as public health systems manage increasing type 2 diabetes prevalence and improve primary care screening. The GCC is characterized by high obesity-linked diabetes rates and strong demand for premium therapies, particularly in countries investing in specialty care, digital health infrastructure, and chronic disease prevention programs.

The European Union offers a harmonized regulatory pathway through the EMA, although market access depends on national reimbursement decisions, health technology assessments, and evidence on clinical value. BRICS markets provide scale, local manufacturing depth, and volume demand, with China, India, and Brazil playing especially important roles in access expansion and pharmaceutical production capacity.

G7 countries lead in innovation, clinical evidence generation, guideline adoption, and premium therapy uptake, supported by mature reimbursement systems and advanced diabetes care infrastructure. NATO markets place growing emphasis on supply-chain resilience, medicine security, and continuity of access for insulin, GLP-1 receptor agonists, SGLT2 inhibitors, and other essential antidiabetic therapies.

Key Country Insights in the Diabetes Drugs Market

The United States leads in diabetes drug innovation, GLP-1 uptake, clinical trial activity, and payer-driven outcomes evidence, supported by a large diagnosed population and established specialty care networks. Canada emphasizes public reimbursement, cost-effectiveness, and equitable access, while Mexico faces a high diabetes burden and continues to expand access to essential antidiabetic medicines and chronic disease management. Brazil represents a major Latin American pharmaceutical market where public procurement, private healthcare demand, and rising type 2 diabetes prevalence support continued use of insulin, oral therapies, and newer drug classes.

In Europe, the United Kingdom, Germany, France, Italy, and Spain balance clinical innovation with HTA requirements, budget controls, guideline-based prescribing, and biosimilar adoption. Germany and France remain influential for reimbursement and clinical practice standards, the United Kingdom emphasizes evidence-based access through national guidance, and Italy and Spain continue to manage diabetes demand through regional healthcare systems. Russia maintains demand for insulin and oral antidiabetic therapies under localization and supply-security pressures.

China and India drive volume demand due to large diabetes populations, rising diagnosis rates, and expanding access to branded, generic, and locally manufactured therapies. Japan supports advanced diabetes care through mature reimbursement and strong adoption of innovative therapies, while Australia combines public reimbursement with structured chronic disease management. South Korea is strengthening diabetes care through advanced healthcare infrastructure, digital health adoption, and increasing use of modern antidiabetic drug classes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated portfolios that combine glucose control with weight, cardiovascular, and kidney benefits. Companies must invest in real-world evidence, head-to-head comparative data, patient adherence tools, and payer-relevant outcomes to support premium positioning for GLP-1 receptor agonists, SGLT2 inhibitors, insulin, and combination therapies.

Operationally, leaders should secure API sourcing, strengthen cold-chain reliability, expand biosimilar and affordable options, and localize access strategies by region. Partnerships with digital health firms, pharmacies, payers, and clinical networks can improve patient engagement and generate data that supports reimbursement, safety monitoring, and long-term brand trust.

Research Methodology

This executive summary is developed using a structured secondary-research framework covering epidemiology, regulatory approvals, treatment guidelines, clinical trial evidence, pharmacovigilance resources, reimbursement policies, and public health datasets. Core references include recognized sources such as the International Diabetes Federation, WHO, CDC, FDA, EMA, OECD, national health agencies, and peer-reviewed clinical literature.

The analysis triangulates disease prevalence, therapeutic class trends, regional access conditions, reimbursement dynamics, and innovation signals. Market interpretation emphasizes verified evidence, consistency across reputable sources, and practical relevance for pharmaceutical manufacturers, biotechnology organizations, payers, distributors, and healthcare strategy teams, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

The diabetes drugs market is entering a more sophisticated phase where efficacy, safety, affordability, supply assurance, and patient outcomes collectively define success. Demand is supported by a large and growing diabetes population, while therapeutic innovation is shifting care toward cardiometabolic and renal protection.

Organizations that align innovation with access will be best positioned to support long-term therapeutic adoption. Strong evidence generation, AI-enabled development, resilient manufacturing, digital engagement, and region-specific commercialization strategies will determine leadership in the global antidiabetic drugs market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Diabetes Drugs Market, by Drug Class

  • 7.1. Amylin Analogs
  • 7.2. GLP-1 Receptor Agonists
  • 7.3. Insulin
    • 7.3.1. Long Acting
    • 7.3.2. Short-Acting
  • 7.4. Oral Antidiabetic Drugs (OADs)

8. Diabetes Drugs Market, by Route Of Administration

  • 8.1. Inhalation
  • 8.2. Injectable
  • 8.3. Oral

9. Diabetes Drugs Market, by Diabetes Type

  • 9.1. Type 1 Diabetes
  • 9.2. Type 2 Diabetes

10. Diabetes Drugs Market, by Drug Origin

  • 10.1. Branded Drugs
  • 10.2. Generic Drugs

11. Diabetes Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Diabetes Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Diabetes Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Diabetes Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Astellas Pharma Inc
  • 16.3. AstraZeneca plc
  • 16.4. Baxter International, Inc.
  • 16.5. Bayer AG
  • 16.6. Biocon Limited
  • 16.7. Bioton S.A.
  • 16.8. Boehringer Ingelheim International GmbH
  • 16.9. Bristol Myers Squibb Company
  • 16.10. Cipla Limited
  • 16.11. Daiichi Sankyo Company Limited
  • 16.12. Eli Lilly and Company
  • 16.13. Eva Pharma
  • 16.14. GlaxoSmithKline plc
  • 16.15. Glenmark Pharmaceuticals Limited
  • 16.16. Gulf Pharmaceutical Industries (Julphar)
  • 16.17. Johnson and Johnson
  • 16.18. Lupin Limited
  • 16.19. MannKind Corporation
  • 16.20. Merck & Co., Inc.
  • 16.21. MJ Biopharm Pvt. Ltd.
  • 16.22. Novartis AG
  • 16.23. Novo Nordisk A S
  • 16.24. Oramed Pharmaceuticals Inc.
  • 16.25. Pfizer Inc
  • 16.26. Roche Holding AG
  • 16.27. Sanofi S A
  • 16.28. Sun Pharmaceutical Industries Ltd
  • 16.29. Takeda Pharmaceutical Company Limited
  • 16.30. Teva Pharmaceutical Industries Ltd
  • 16.31. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 16.32. Viatris Inc.
  • 16.33. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DIABETES DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DIABETES DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DIABETES DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHORT-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHORT-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 109. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 112. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. G7 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 130. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 133. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 137. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 140. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. CANADA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRAZIL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)